首页> 外文期刊>Liver international : >Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE
【24h】

Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE

机译:通过二维DIGE鉴定HCV感染的肝硬化患者血浆中肝细胞癌的候选生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The current methods available for screening and detecting hepatocellular carcinoma (HCC) have insufficient sensitivity and specificity, and only a low percentage of diagnosis of small tumours is based on these assays. Because HCC is usually asymptomatic at potentially curative stages, identification of biomarkers for the early detection of HCC is essential to improve patient survival. Aim: The aim of this study was to identify candidate markers for HCC development in the plasma from hepatitis C virus (HCV)-infected cirrhotic patients. Methods: We compared protein expression profiles of plasma samples from HCV-infected cirrhotic patients with and without HCC, using two-dimensional fluorescence difference gel electrophoresis (2-D DIGE) coupled with MALDI-TOF/TOF mass spectrometry. The 2-D DIGE results were analysed statistically using Decyder? software, and verified by western blot and enzyme-linked immunosorbent assay (ELISA). Results: In the plasma of HCV-infected HCC patients, we observed decreased expression of complement component 9, ficolin-3 (FCN3), serum amyloid P component (SAP), fibrinogen-gamma and immunoglobulin gamma-1 chain, and increased expression of vitronectin (VTN) and galectin-3 binding protein (G3BP) by DIGE analysis. ELISA confirmed DIGE results for VTN and G3BP but not for SAP or FCN3 in a larger patient population. Conclusions: The proteins VTN and SAP are candidate biomarkers for HCC development in HCV-infected cirrhotic patients.
机译:背景:目前可用于筛查和检测肝细胞癌(HCC)的方法敏感性和特异性不足,并且基于这些测定法的小肿瘤诊断率很低。由于HCC在潜在的治愈阶段通常是无症状的,因此为早期检测HCC识别生物标志物对于提高患者生存率至关重要。目的:本研究的目的是确定感染丙型肝炎病毒(HCV)的肝硬化患者血浆中肝癌发生的候选标记。方法:我们使用二维荧光差值凝胶电泳(2-D DIGE)结合MALDI-TOF / TOF质谱,比较了HCV感染的肝硬化患者(无论是否患有HCC)血浆样品的蛋白质表达谱。使用Decyder?统计分析二维DIGE结果。软件,并通过蛋白质印迹和酶联免疫吸附测定(ELISA)进行了验证。结果:在感染HCV的HCC患者的血浆中,我们观察到补体成分9,ficolin-3(FCN3),血清淀粉样P成分(SAP),纤维蛋白原-γ和免疫球蛋白γ-1链的表达降低,并且通过DIGE分析玻连蛋白(VTN)和半乳糖凝集素3结合蛋白(G3BP)。 ELISA证实在较大的患者群体中VTN和G3BP的DIGE结果,但SAP或FCN3的DIGE结果没有。结论:VTN和SAP蛋白是HCV感染肝硬化患者肝癌发展的候选生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号